Free Trial

Biohaven (BHVN) Stock Price, News & Analysis

Biohaven logo
$13.71 -0.36 (-2.54%)
As of 11:41 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Biohaven Stock (NYSE:BHVN)

Key Stats

Today's Range
$13.77
$14.15
50-Day Range
$12.81
$16.21
52-Week Range
$12.79
$55.70
Volume
409,543 shs
Average Volume
1.73 million shs
Market Capitalization
$1.45 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.71
Consensus Rating
Buy

Company Overview

Biohaven Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
66th Percentile Overall Score

BHVN MarketRank™: 

Biohaven scored higher than 66% of companies evaluated by MarketBeat, and ranked 360th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Biohaven has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 12 buy ratings, 1 hold rating, and no sell ratings.

  • Upside Potential

    Biohaven has a consensus price target of $55.71, representing about 303.1% upside from its current price of $13.82.

  • Amount of Analyst Coverage

    Biohaven has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Biohaven's stock forecast and price target.
  • Earnings Growth

    Earnings for Biohaven are expected to grow in the coming year, from ($8.90) to ($6.28) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Biohaven is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Biohaven is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Biohaven has a P/B Ratio of 3.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Biohaven's valuation and earnings.
  • Percentage of Shares Shorted

    11.98% of the float of Biohaven has been sold short.
  • Short Interest Ratio / Days to Cover

    Biohaven has a short interest ratio ("days to cover") of 5.3.
  • Change versus previous month

    Short interest in Biohaven has recently decreased by 2.92%, indicating that investor sentiment is improving.
  • Dividend Yield

    Biohaven does not currently pay a dividend.

  • Dividend Growth

    Biohaven does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.98% of the float of Biohaven has been sold short.
  • Short Interest Ratio / Days to Cover

    Biohaven has a short interest ratio ("days to cover") of 5.3.
  • Change versus previous month

    Short interest in Biohaven has recently decreased by 2.92%, indicating that investor sentiment is improving.
  • News Sentiment

    Biohaven has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.93 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 45 news articles for Biohaven this week, compared to 19 articles on an average week.
  • Search Interest

    104 people have searched for BHVN on MarketBeat in the last 30 days. This is an increase of 1,056% compared to the previous 30 days.
  • MarketBeat Follows

    Only 4 people have added Biohaven to their MarketBeat watchlist in the last 30 days. This is a decrease of -64% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Biohaven insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.00% of the stock of Biohaven is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    88.78% of the stock of Biohaven is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Biohaven's insider trading history.
Receive BHVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BHVN Stock News Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.tc pixel
See More Headlines

BHVN Stock Analysis - Frequently Asked Questions

Biohaven's stock was trading at $37.35 at the beginning of 2025. Since then, BHVN stock has decreased by 63.0% and is now trading at $13.82.

Biohaven Ltd. (NYSE:BHVN) posted its quarterly earnings data on Monday, August, 11th. The company reported ($1.94) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($1.94).

Biohaven (BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Biohaven's top institutional shareholders include Bellevue Group AG (2.65%), JPMorgan Chase & Co. (2.52%), Armistice Capital LLC (2.02%) and Geode Capital Management LLC (1.99%). Insiders that own company stock include John W Childs, Vlad Coric, Gregory Bailey, Matthew Buten and Irina Antonijevic.
View institutional ownership trends
.

Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Biohaven investors own include NVIDIA (NVDA), Humana (HUM), Invesco QQQ (QQQ), Meta Platforms (META), American Water Works (AWK), Broadcom (AVGO) and Voyager Therapeutics (VYGR).

Company Calendar

Last Earnings
8/11/2025
Today
9/12/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:BHVN
Previous Symbol
NASDAQ:BHVN
CIK
1935979
Fax
N/A
Employees
239
Year Founded
2014

Price Target and Rating

High Price Target
$76.00
Low Price Target
$21.00
Potential Upside/Downside
+294.3%
Consensus Rating
Buy
Rating Score (0-4)
3.13
Research Coverage
16 Analysts

Profitability

EPS (Trailing Twelve Months)
($7.66)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$846.42 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-270.65%
Return on Assets
-143.70%

Debt

Debt-to-Equity Ratio
1.91
Current Ratio
3.82
Quick Ratio
3.82

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.19 per share
Price / Book
3.37

Miscellaneous

Outstanding Shares
105,790,000
Free Float
88,864,000
Market Cap
$1.49 billion
Optionable
Optionable
Beta
1.02

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NYSE:BHVN) was last updated on 9/12/2025 by MarketBeat.com Staff
From Our Partners